Financial Performance - Revenue for Q3 2025 reached 9.09 billion CNY, showing a year-on-year growth of 18.7% [1] - Net profit attributable to shareholders was 2.50 billion CNY, with a year-on-year increase of 30.0% [1] - Operating cash flow stood at 3.35 billion CNY, reflecting a slight decline of 1.5% year-on-year [1] - Projected revenue growth for Q4 2025 is expected to accelerate compared to Q3 [1] Shareholder Returns - Since its A-share listing in 2018, the company has implemented dividends for 7 consecutive years [1] - Total dividends distributed by September 30, 2025, amounted to approximately 35.7 billion CNY, which is 6 times the IPO fundraising of 5.9 billion CNY [1] - The company plans to distribute cash dividends of 1.71 billion CNY in May 2025, 1.59 billion CNY in September 2025, and 1.64 billion CNY in October 2025 [1] Business Segments International Business - International revenue for Q3 2025 was 4.60 billion CNY, with a year-on-year growth of 11.9% [4] - International business accounted for 50.6% of total revenue, with Europe showing over 20% growth [4] - The international revenue share for the first three quarters reached 70% [1] Domestic Business - Domestic revenue for Q3 2025 was 4.49 billion CNY, down 7.3% year-on-year [4] - Recovery in domestic equipment business began in Q3 due to resumed medical equipment bidding activities [4] R&D and Innovation - R&D investment for the first three quarters was 2.686 billion CNY, representing 10.40% of total revenue [4] - The company has applied for a total of 12,513 patents, with 6,355 patents granted [4] - Key products include high-sensitivity cardiac troponin T assay kits and perioperative decision support systems [4] Market Expansion - The "Smart Laboratory" solution has been installed in over 900 hospitals nationwide, with 80% being tertiary hospitals [7] - The solution has also been implemented in countries like Jordan, Indonesia, and Romania, enhancing local laboratory capabilities [8] Social Responsibility - The company organized 375 first aid training sessions, training 15,891 individuals, and has successfully treated 415 cardiac arrest patients using AEDs [17] - Collaborated with Mercy Ships to provide medical equipment and training for free surgeries in Africa [18]

Financial Performance - Total revenue for the first half of 2025 reached 167.4 billion CNY, with a net profit of 50.7 billion CNY [1] - Total assets amounted to 587.7 billion CNY, and net assets were 440.2 billion CNY [1] - The company anticipates positive year-on-year revenue growth in Q3 2025, continuing a trend of quarterly improvement [1] Shareholder Returns - The company announced a cash dividend of 17.1 billion CNY (before tax) for the first mid-term distribution in April 2025 [1] - A second mid-term cash dividend of 15.9 billion CNY (before tax) is planned for August 2025 [1] - The annual profit distribution will be at least 65% of the distributable profit [1] Business Segments In Vitro Diagnostics - Revenue from in vitro diagnostics reached 64.2 billion CNY, accounting for 38.4% of total revenue, with a double-digit year-on-year growth [1] - International chemical luminescence business grew by over 20% year-on-year [1] - The company sold 13 sets of the MT 8000 fully automated laboratory intelligent assembly line, with a total of 15 sets sold [1] Medical Imaging - Revenue from medical imaging was 33.1 billion CNY, representing 19.8% of total revenue [1] - The company has established a strong presence in the international market, with significant growth expected in Q3 2025 [3] Life Information and Support - Revenue from life information and support reached 54.8 billion CNY, making up 32.7% of total revenue [1] R&D and Innovation - R&D investment for the reporting period was 17.8 billion CNY, constituting 10.6% of total revenue [3] - The company has applied for a total of 12,240 patents, with 6,126 granted, including 3,085 invention patents [3] Market Expansion - The "瑞检生态" smart laboratory solution has been installed in nearly 800 hospitals, with 80% being tertiary hospitals [4] - The company has expanded its international footprint, with installations in countries like Jordan, Indonesia, Thailand, and Romania [7] Sustainable Development - The company maintained an MSCI ESG rating of AA for the third consecutive year and was included in the S&P Global Sustainable Development Yearbook (China Edition) [15] - Over 230,000 individuals participated in emergency training, with 9,008 people trained in 201 events [15]